IN2012DN02645A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02645A
IN2012DN02645A IN2645DEN2012A IN2012DN02645A IN 2012DN02645 A IN2012DN02645 A IN 2012DN02645A IN 2645DEN2012 A IN2645DEN2012 A IN 2645DEN2012A IN 2012DN02645 A IN2012DN02645 A IN 2012DN02645A
Authority
IN
India
Prior art keywords
adamts13
formulations
various diseases
present
conditions
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Matthiessen H
L Turecek Peter
Schwarz Hans-Peter
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of IN2012DN02645A publication Critical patent/IN2012DN02645A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24087ADAMTS13 endopeptidase (3.4.24.87)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2645DEN2012 2009-09-21 2010-09-21 IN2012DN02645A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21
PCT/US2010/049723 WO2011035335A2 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations

Publications (1)

Publication Number Publication Date
IN2012DN02645A true IN2012DN02645A (es) 2015-09-11

Family

ID=43598388

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2645DEN2012 IN2012DN02645A (es) 2009-09-21 2010-09-21

Country Status (21)

Country Link
US (8) US8623352B2 (es)
EP (4) EP2480198B9 (es)
JP (2) JP5819303B2 (es)
KR (5) KR20220139456A (es)
CN (2) CN104224705B (es)
AU (1) AU2010295299B2 (es)
BR (1) BR112012006283B1 (es)
CA (1) CA2774556A1 (es)
DK (3) DK3834841T3 (es)
EA (1) EA024267B1 (es)
ES (3) ES2948612T3 (es)
FI (1) FI3834841T3 (es)
HK (1) HK1173968A1 (es)
HR (1) HRP20160295T1 (es)
HU (1) HUE028688T2 (es)
IN (1) IN2012DN02645A (es)
MX (3) MX339205B (es)
NZ (1) NZ598839A (es)
PL (3) PL3167897T3 (es)
PT (1) PT3834841T (es)
WO (1) WO2011035335A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009322367B2 (en) 2008-12-05 2015-03-26 Takeda Pharmaceutical Company Limited Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
ES2948612T3 (es) * 2009-09-21 2023-09-14 Takeda Pharmaceuticals Co Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas
EP2814514B1 (en) * 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
US10441531B2 (en) * 2012-11-09 2019-10-15 Bloodworks Protein stabilizing factors
JP6397479B2 (ja) 2013-03-15 2018-09-26 エータイアー ファーマ, インコーポレイテッド ヒスチジル−tRNAシンテターゼFcコンジュゲート
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
EP4285930A3 (en) * 2014-06-26 2024-02-28 Amgen Inc. Protein formulations
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
JP7002727B2 (ja) * 2016-01-08 2022-02-15 Kmバイオロジクス株式会社 Adamts13を主成分とする診断薬および医薬品
MX2019001255A (es) * 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
JP2019537578A (ja) 2016-11-04 2019-12-26 バクスアルタ インコーポレイテッド アデノ随伴ウイルス製剤
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
SG11202012946RA (en) * 2018-07-11 2021-02-25 Baxalta Inc Aav compositions
BR112022019817A2 (pt) 2020-04-02 2022-12-06 Takeda Pharmaceuticals Co Variante de adamts13, composições e usos das mesmas
JP2023526546A (ja) 2020-05-22 2023-06-21 武田薬品工業株式会社 コロナウイルス疾患の合併症の治療及び診断のための、adamts13組成物及び方法
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CN101810854A (zh) 1999-02-22 2010-08-25 巴克斯特国际公司 新的无白蛋白的因子viii制剂
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子(vWF)切断酵素
AU2002336367A1 (en) * 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
EP1642128B1 (en) * 2003-07-07 2016-11-16 University Of North Carolina At Chapel Hill Method and system for detection of von willebrand factor (vwf) multimers
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006133955A1 (en) 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
JP4880997B2 (ja) * 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Adamts13の安定化方法
DK2522717T3 (da) 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
ES2948612T3 (es) * 2009-09-21 2023-09-14 Takeda Pharmaceuticals Co Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
ES2948612T3 (es) 2023-09-14
US20180207245A1 (en) 2018-07-26
CN102573792A (zh) 2012-07-11
MX2012003414A (es) 2012-06-19
KR101891646B1 (ko) 2018-08-27
KR20120099646A (ko) 2012-09-11
PL3834841T3 (pl) 2023-07-24
EP4218797A1 (en) 2023-08-02
US20140178357A1 (en) 2014-06-26
KR20220139456A (ko) 2022-10-14
HK1173968A1 (zh) 2013-05-31
MX339205B (es) 2016-05-16
US10758599B2 (en) 2020-09-01
US8623352B2 (en) 2014-01-07
AU2010295299B2 (en) 2015-12-24
HUE028688T2 (en) 2017-01-30
EP2480198B1 (en) 2016-03-09
JP5819303B2 (ja) 2015-11-24
CA2774556A1 (en) 2011-03-24
PL3167897T3 (pl) 2021-09-27
BR112012006283B1 (pt) 2022-03-15
BR112012006283A2 (pt) 2016-05-31
WO2011035335A3 (en) 2011-12-01
KR20180095738A (ko) 2018-08-27
US9937244B2 (en) 2018-04-10
EP2480198A2 (en) 2012-08-01
PT3834841T (pt) 2023-06-19
HRP20160295T1 (hr) 2016-05-20
DK3834841T3 (da) 2023-06-06
US20230130866A1 (en) 2023-04-27
ES2579906T3 (es) 2016-08-17
MX2019000547A (es) 2020-11-12
MX362382B (es) 2019-01-14
EA024267B1 (ru) 2016-09-30
EP2480198B9 (en) 2016-11-23
PL2480198T3 (pl) 2016-09-30
DK2480198T3 (en) 2016-03-29
DK3167897T3 (da) 2021-04-19
AU2010295299A1 (en) 2012-04-12
US20200376098A1 (en) 2020-12-03
KR20190137954A (ko) 2019-12-11
EA201200519A1 (ru) 2012-09-28
US9572778B2 (en) 2017-02-21
EP3167897A1 (en) 2017-05-17
US20170112906A1 (en) 2017-04-27
JP2015063556A (ja) 2015-04-09
KR20210054598A (ko) 2021-05-13
EP3834841B1 (en) 2023-05-17
ES2865250T3 (es) 2021-10-15
JP2013505270A (ja) 2013-02-14
US20160375111A1 (en) 2016-12-29
US11564979B2 (en) 2023-01-31
CN104224705B (zh) 2018-02-02
US20190247475A1 (en) 2019-08-15
CN104224705A (zh) 2014-12-24
WO2011035335A2 (en) 2011-03-24
FI3834841T3 (fi) 2023-06-05
CN102573792B (zh) 2014-10-15
US20110229455A1 (en) 2011-09-22
NZ598839A (en) 2014-03-28
EP3167897B1 (en) 2021-01-27
US9351935B2 (en) 2016-05-31
EP3834841A1 (en) 2021-06-16
US10238720B2 (en) 2019-03-26

Similar Documents

Publication Publication Date Title
IN2012DN02645A (es)
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
UA115983C2 (uk) Інгібітори днк-пк
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IN2012DN02737A (es)
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
IN2012DN02735A (es)
IN2012DN00754A (es)
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2013004061A (es) Analogos de ciclosporina.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2013004062A (es) Analogos de ciclosporina.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
WO2007138382A3 (en) Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy